Detalles de la búsqueda
1.
Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Diabetologia
; 67(7): 1328-1342, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38509341
2.
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Cardiovasc Diabetol
; 23(1): 57, 2024 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38331813
3.
Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
Am Heart J
; 254: 203-215, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36150454
4.
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes Obes Metab
; 24(3): 442-454, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34729891
5.
Confirming diagnoses of acute pancreatitis with commonly available electronic data.
Pharmacoepidemiol Drug Saf
; 30(3): 313-319, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368819
6.
Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.
J Am Soc Nephrol
; 31(7): 1594-1601, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487562
7.
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Circulation
; 139(25): 2822-2830, 2019 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30955357
8.
Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States from 2010 to 2014.
Diabetes Obes Metab
; 22(7): 1132-1140, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32090430
9.
Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
BMC Nephrol
; 21(1): 167, 2020 05 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32380961
10.
Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
BMC Nephrol
; 21(1): 200, 2020 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32466752
11.
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Cardiovasc Diabetol
; 23(1): 103, 2024 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38500096
12.
Multimorbidity: can general practitioners identify the health conditions most important to their patients? Results from a national cross-sectional study in Switzerland.
BMC Fam Pract
; 19(1): 66, 2018 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-29776442
13.
From chronic conditions to relevance in multimorbidity: a four-step study in family medicine.
Fam Pract
; 33(4): 439-44, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27154549
14.
[Multimorbidity in primary care from GPs' and patients' perspectives: a national database]. / La multimorbidité en médecine de famille du point de vue du médecin et du patient: une banque de données nationale.
Rev Med Suisse
; 12(518): 922, 924-7, 2016 May 11.
Artículo
en Francés
| MEDLINE | ID: mdl-27352586
15.
[Prioritization strategies in the care of multimorbid patients in family medicine]. / Stratégies de priorisation dans la prise en charge des patients multimorbides en médecine de famille.
Rev Med Suisse
; 12(518): 928-31, 2016 May 11.
Artículo
en Francés
| MEDLINE | ID: mdl-27352587
16.
Poor adherence to and persistence with biologics in generalized pustular psoriasis: A claim-based study using real-world data from two large US databases.
JAAD Int
; 15: 78-83, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38440298
17.
The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction.
Int J Cardiol Heart Vasc
; 47: 101182, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37583714
18.
Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
J Diabetes Investig
; 14(3): 417-428, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36716212
19.
Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology.
Clin Pharmacol Ther
; 114(3): 604-613, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37342987
20.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes Metab
; 49(2): 101418, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608816